Fig. 2From: Evaluation of sensitivity and specificity of CanPatrol™ technology for detection of circulating tumor cells in patients with non-small cell lung cancerThe ROC curve of CanPatrol™ technology-based CTCs of NSCLC. There were 38 benign patients, including 33 CTC negative and 5 CTC positive patients; and 98 NSCLC patients, including 18 CTC negative and 80 CTC positive patientsBack to article page